Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
39187485
PubMed Central
PMC11347579
DOI
10.1038/s41408-024-01131-6
PII: 10.1038/s41408-024-01131-6
Knihovny.cz E-zdroje
- MeSH
- chromozomální delece MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 1 genetika MeSH
- mnohočetný myelom * komplikace diagnóza MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
Zobrazit více v PubMed
Neupane K, Fortuna GG, Dahal R, Schmidt TM, Fonseca R, Chakraborty R, et al. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J. 2024;14:20–30. 10.1038/s41408-024-00985-0 10.1038/s41408-024-00985-0 PubMed DOI PMC
Jiménez-Segura R, Rosiñol L, Cibeira MT, Fernández de Larrea C, Tovar N, Rodríguez-Lobato LG, et al. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. 2022;12:135. 10.1038/s41408-022-00730-5 PubMed DOI PMC
Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019;36:32–9. 10.1016/j.blre.2019.04.002 10.1016/j.blre.2019.04.002 PubMed DOI
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. 10.1182/blood.2022015851 10.1182/blood.2022015851 PubMed DOI PMC
Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 2016;97:93–100. 10.1111/ejh.12688 PubMed DOI
Xia Y, Shi Y, Chen Z, Zhang J, Zhu Y, Guo R, et al. Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma. Chin Med J. 2022;135:2500–2. 10.1097/CM9.0000000000002351 10.1097/CM9.0000000000002351 PubMed DOI PMC
Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rao M, et al. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol 2020;44:838–48. 10.1097/PAS.0000000000001459 10.1097/PAS.0000000000001459 PubMed DOI PMC
Jelinek T, Zihala D, Sevcikova T, Anilkumar SA, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38:1323–33. 10.1038/s41375-024-02206-w 10.1038/s41375-024-02206-w PubMed DOI PMC
Locher M, Steurer M, Jukic E, Keller MA, Fresser F, Ruepp C, et al. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. Am J Hematol 2020;95:1562–71. 10.1002/ajh.25994 10.1002/ajh.25994 PubMed DOI PMC
Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28:675–9. 10.1038/leu.2013.225 10.1038/leu.2013.225 PubMed DOI PMC
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023;141:1308–15. 10.1182/blood.2022017863 10.1182/blood.2022017863 PubMed DOI PMC
Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–4. 10.3324/haematol.2013.094409 10.3324/haematol.2013.094409 PubMed DOI PMC
